Systematic review and meta-analysis comparing the autogenous vein bypass versus a prosthetic graft for above-the-knee femoropopliteal bypass surgery in patients with intermittent claudication

• Published in: Vascular Vol. 32; no. 1; p. 91
• Main Authors: Vossen, R J, Fokkema, T M, Vahl, A C, Balm, R
• Format: Journal Article
• Language: English
• Published: England 01.02.2024
• Subjects: Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation - adverse effects; Femoral Artery - diagnostic imaging; Femoral Artery - surgery; Humans; Intermittent Claudication - diagnostic imaging; Intermittent Claudication - surgery; Lower Extremity - blood supply; Peripheral Arterial Disease - diagnostic imaging; Peripheral Arterial Disease - surgery; Polytetrafluoroethylene; Popliteal Artery - diagnostic imaging; Popliteal Artery - surgery; Saphenous Vein; Vascular Patency; femoropopliteal bypass surgery; peripheral artery disease; bypass graft; intermittent claudication
• ISSN: 1708-539X
• DOI: 10.1177/17085381221124701

According to guidelines, the autogenous saphenous vein (ASV) is the preferred conduit for femoropopliteal bypass surgery in all patients with peripheral artery disease. However, in contrast to patients with critical limb ischemia (CLI), patients with intermittent claudication (IC) only, tend to have milder disease, and thus a prosthetic graft may be as good as a vein conduit. The objective of this study was to compare patency rates of the ASV and a prosthetic graft in femoropopliteal bypass surgery in patients with IC. A systematic literature search was performed in the PubMed, Embase, and Cochrane databases to identify randomized controlled trials comparing prosthetic graft versus ASV in patients with IC. Articles with a mixed IC and CLI study population were included if more than 50% of the study cohort was treated for IC. Primary analysis was performed on IC patients only. Secondary analysis was performed on the mixed group. The primary endpoint was short- and long-term patency and secondary endpoints were complications, limb salvage, and mortality. In total, six studies with 524 patients were included. Only two studies reported solely on patients with IC. All these patients underwent above-the-knee bypasses and average patency rates at one and 5 years were 88% and 76% vs 81% and 68% in the ASV and the PTFE groups, respectively. One and five-year patency was not statistically different between the groups (OR 5.21; 95% CI 0.60-45.36 and OR 2.10; 95% CI 0.88-5.01). In a mixed population of patients with IC and CLI (84% IC patients), 1 year patency was comparable (OR 1.40; 95% CI 0.87-2.25). However, after a follow-up of over 3 years, this mixed group had significantly higher patency rates in favour of the ASV (OR 2.06; 95 % CI 1.30-3.26). Complication and amputation rates were comparable in both groups. Limited data are available for patients receiving above-the-knee femoropopliteal bypass for intermittent claudication. The ASV remains the conduit of choice for femoropopliteal bypass surgery. However, the prosthetic conduit seems a feasible alternative for patients with intermittent claudication in whom the ASV is not present or unsuitable.